Gland Pharma Ltd Financials
Company Logo

Gland Pharma Ltd Financial Statement

Gland Pharma Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Mar 2025
Revenue1074.07
Operating Expense636.23
Net Profit290.00
Net Profit Margin27.00
Earning Per Share17.60
EBIDTA435.59
Effective Tax Rate22.63

Gland Pharma Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual4,167.43
Operating Expenses Annual2,758.65
Operating Profit Annual1,575.45
Interest Annual7.84
Depreciation157.99
Net Profit Annual1,043.33
Tax Annual362.17

Gland Pharma Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning1,905.22
Cash Flow from Operations1,135.97
Cash Flow from Investing-2,917.58
Cash Flow from Financing-7.40
Cash Flow at the End116.21

Gland Pharma Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)37.80
PBIT Margin (%)33.91
PBT Margin (%)29.58
Net PROFIT Margin (%)25.04
Return On Networth / Equity (%)12.31
Return On Networth /Employed (%)16.65
Return On Assets (%)12.27
Total Debt / Equity (X)TBA
Asset Turnover Ratio (%)0.49

Gland Pharma Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual1,693.73
Total Current Assets Annual4,571.33
Non Current Assets Annual4,969.76
Total Shareholders Funds Annual8,995.29
Total Assets Annual9,541.09

Gland Pharma Ltd Earning Calls

EPS (INR)

Expected

11.32

Reported

11.32

Surprise

0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.00%

Jun 2024

EPS beaten by 0.10%

FAQS on Gland Pharma Ltd Financials

As of Jun 1, 2025, Gland Pharma Ltd has a market capitalization of 26,232.52 Cr. Value Research classifies it as a Large-Cap company.

Yes, Gland Pharma Ltd is with a debt-to-equity ratio of 0.00.

In FY 2024 , Gland Pharma Ltd recorded a total revenue of approximately 4,116.15 Cr marking a significant milestone in the company's financial performance.

Gland Pharma Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.1% and 0.1% annually, respectively..

Gland Pharma Ltd's current PE ratio is 24.07.

Gland Pharma Ltd's ROCE averaged 14.7% from the FY ending March 2023 to 2025, with a median of 15.2%. It peaked at 15.7% in March 2024, reflecting strong capital efficiency over the period..

Gland Pharma Ltd's latest EBIT is Rs. 1,488.43 Cr, surpassing the average EBIT of Rs. 1,319.19 Cr over the 5 years..

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions